Kannalife, Inc. announced the filing of a new U.S. Patent for its proprietary and novel CBD-like molecules to treat radiation dermatitis (RD) and other skin disorders. The major side effect of RD is skin tissue damage also known as radiodermatitis which occurs in 95% of cancer patients receiving radiation therapy (RT). While acute inflammation is observed within hours of RT, this painful and common side effect develops over weeks and its severity with time progresses to erythema, dry or wet desquamation or ulceration. Currently, no single agent has been shown to completely alleviate the radiation dermatitis side effect. Current therapies that focus on the symptoms include corticosteroid cream, antibiotics, zinc and amifostine. Because of the widespread incidence and the paucity of completely effective therapies, there is an urgent need for new and effective therapies, particularly those employing small molecules that are directed on regulating free radicals and decreasing the concentration of mediators of inflammation which are largely cytokines. A December 2017 report by Transparency Market Research projects the radiodermatitis market to reach $420 million by 2024.